Literature DB >> 24366351

Comparing diabetes medications: where do we set the bar?

Kasia J Lipska1, Harlan M Krumholz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24366351      PMCID： PMC5459364          DOI： 10.1001/jamainternmed.2013.13433

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  7 in total

1.  Redefining quality--implications of recent clinical trials.

Authors:  Harlan M Krumholz; Thomas H Lee
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

2.  The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.

Authors:  William R Hiatt; Sanjay Kaul; Robert J Smith
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

3.  A clinical trial to maintain glycemic control in youth with type 2 diabetes.

Authors:  Phil Zeitler; Kathryn Hirst; Laura Pyle; Barbara Linder; Kenneth Copeland; Silva Arslanian; Leona Cuttler; David M Nathan; Sherida Tollefsen; Denise Wilfley; Francine Kaufman
Journal:  N Engl J Med       Date:  2012-04-29       Impact factor: 91.245

4.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

5.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

6.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112

7.  Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

Authors:  David M Nathan; John B Buse; Steven E Kahn; Heidi Krause-Steinrauf; Mary E Larkin; Myrlene Staten; Deborah Wexler; John M Lachin
Journal:  Diabetes Care       Date:  2013-05-20       Impact factor: 19.112
  7 in total
  3 in total

1.  Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.

Authors:  Reimar W Thomsen; Lisbeth M Baggesen; Mette Søgaard; Lars Pedersen; Helene Nørrelund; Esben S Buhl; Christiane L Haase; Søren P Johnsen
Journal:  Diabetologia       Date:  2015-08-16       Impact factor: 10.122

Review 2.  Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.

Authors:  James H Flory; Jenny K Ukena; James S Floyd
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

Review 3.  Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM).

Authors:  Marcello Casaccia Bertoluci; Rodrigo Oliveira Moreira; André Faludi; Maria Cristina Izar; Beatriz D Schaan; Cynthia Melissa Valerio; Marcelo Chiara Bertolami; Ana Paula Chacra; Marcus Vinicius Bolivar Malachias; Sérgio Vencio; José Francisco Kerr Saraiva; Roberto Betti; Luiz Turatti; Francisco Antonio Helfenstein Fonseca; Henrique Tria Bianco; Marta Sulzbach; Adriana Bertolami; João Eduardo Nunes Salles; Alexandre Hohl; Fábio Trujilho; Eduardo Gomes Lima; Marcio Hiroshi Miname; Maria Teresa Zanella; Rodrigo Lamounier; João Roberto Sá; Celso Amodeo; Antonio Carlos Pires; Raul D Santos
Journal:  Diabetol Metab Syndr       Date:  2017-07-14       Impact factor: 3.320
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.